Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • E-4031: Mechanistic Insights and Future Frontiers in Card...

    2026-03-22

    E-4031: Mechanistic Insights and Future Frontiers in Cardiac Ion Channel Pharmacology

    Introduction

    Cardiac electrophysiology research has long relied on pharmacological agents to probe the intricacies of ion channel signaling and arrhythmia mechanisms. Among these, E-4031 (SKU B6077) stands out as a gold-standard antiarrhythmic agent, renowned for its selective inhibition of the hERG (human Ether-à-go-go-Related Gene) potassium channel. While previous reviews have highlighted its utility in routine hERG blockade and cardiac action potential studies, this article delves deeper—unpacking the molecular pharmacology, advanced 3D modeling applications, and the transformative role of E-4031 in next-generation cardiac safety and disease modeling. By synthesizing recent advances in 3D electrophysiological mapping and integrating the latest research platforms, we chart a distinct path beyond conventional applications and existing product guides.

    Mechanism of Action: E-4031 as a Selective hERG Potassium Channel Blocker

    E-4031 is chemically defined as N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide (molecular weight: 401.52, CAS: 113558-89-7). Its mechanism is centered on its high-affinity, selective blockade of the hERG potassium channel—a critical component of cardiac repolarization. The hERG channel mediates the rapid delayed rectifier potassium current (IKr), which governs the final phase of the cardiac action potential. E-4031 exhibits an IC50 of 7.7 nM for hERG, enabling precise ATP-sensitive potassium channel inhibition and direct modulation of membrane excitability across various tissues, including myocardium, pancreatic beta cells, and neuronal networks.

    Pharmacodynamically, E-4031 prolongs the cardiac action potential duration and cycle length, induces depolarization of the maximum diastolic potential, and reduces both the upstroke velocity and diastolic depolarization rate. These effects are instrumental in modeling and dissecting arrhythmogenic events such as early afterdepolarizations (EADs) and torsades de pointes (TdP)—hallmarks of drug-induced arrhythmia and long QT syndrome. In vivo, E-4031 leads to a delay in cardiac repolarization, prolongation of the QT interval, and alteration of the activation-recovery interval (ARI), especially pronounced in the mid-myocardium during bradycardia. These mechanistic features make E-4031 an invaluable reference compound in cardiac ion channel pharmacology and preclinical antiarrhythmic drug development.

    Beyond the Bench: E-4031 in Advanced Cardiac Electrophysiology Platforms

    Limitations of Traditional Approaches

    Historically, the application of E-4031 has been confined to 2D cell cultures and monolayer electrophysiological studies using patch clamp or planar microelectrode arrays (MEAs). While these models provide high temporal resolution and control, they fail to recapitulate the heart’s native 3D structure, cellular heterogeneity, and complex conduction pathways. This limitation restricts the translational value of arrhythmia research and hinders accurate preclinical cardiac safety testing.

    3D Cardiac Organoids and Shell Microelectrode Arrays: A Paradigm Shift

    The emergence of 3D cardiac organoids derived from human induced pluripotent stem cells (iPSCs) has transformed the landscape of cardiac disease modeling. These organoids mimic key aspects of cardiac cytoarchitecture, enabling the study of spontaneous and evoked action potentials, tissue-level arrhythmogenic events, and myocardial conduction velocities. However, capturing the full spectrum of 3D electrical activity requires novel bioelectronic interfaces.

    A recent breakthrough, as demonstrated by Choi et al. (2025, Adv. Mater.), introduced programmable, shape-adaptive shell microelectrode arrays (MEAs) capable of encapsulating entire organoids. Unlike traditional 2D MEAs, shell MEAs provide high-resolution, 3D spatiotemporal mapping of electrical activity, conduction velocity, and arrhythmogenic substrate development. Critically, these platforms facilitate non-destructive, longitudinal studies—enabling direct pharmacological interrogation with agents like E-4031 and integration with multimodal readouts such as calcium imaging.

    E-4031 as a Tool for Proarrhythmic Substrate Modeling in 3D

    By leveraging the unique capabilities of shell MEAs, researchers have applied E-4031 to induce and characterize proarrhythmic substrates within 3D organoids. This approach enables the direct observation of QT interval prolongation, EADs, and TdP induction in physiologically relevant, multicellular contexts. The result is a more predictive and granular assessment of cardiac repolarization delay, electro-mechanical coupling, and the risk profile of candidate compounds. Such advances mark a substantial departure from earlier studies focused on 2D models, as highlighted in articles like "E-4031 (SKU B6077): Reliable hERG Blockade for Cardiac El...", which primarily emphasize assay reproducibility and selectivity in simplified systems. Here, we extend the application scope, using E-4031 to interrogate arrhythmia mechanisms within complex 3D tissue architectures.

    Comparative Analysis: E-4031 versus Alternative Ion Channel Blockers

    While numerous potassium channel blockers exist, E-4031 is distinguished by its selectivity for the hERG/IKr channel and its robust pharmacological profile. Many alternative agents, such as dofetilide and sotalol, exhibit off-target effects or differing affinities for other cardiac ion channels, complicating interpretation in mechanistic studies. E-4031’s high purity (≥98%) and validated quality control (HPLC, NMR) as supplied by APExBIO further ensure consistent performance in both in vitro and in vivo platforms.

    Importantly, E-4031’s solubility characteristics (insoluble in water; ≥103 mg/mL in DMSO; ≥9.66 mg/mL in ethanol with mild heating and sonication) and stability profile (recommended storage at -20°C, short-term solution use) support its application across diverse experimental settings. This reliability underpins its role as the reference standard for selective IKr channel inhibition in cardiac electrophysiology and pharmacological modulation of IKr.

    While previous reviews, such as "E-4031 (SKU B6077): Precision hERG Blockade for Cardiac E...", provide evidence-based implementation guides and protocol insights, our focus here is on advancing the functional and translational context—particularly through the integration of E-4031 in 3D disease modeling and high-content screening platforms.

    Expanding Frontiers: E-4031 in Preclinical Cardiac Safety and Disease Modeling

    Innovations in Preclinical Cardiac Safety Testing

    The proarrhythmic liability of candidate drugs remains a major concern in pharmaceutical development. As a result, in vitro preclinical cardiac safety testing increasingly employs E-4031 to model drug-induced arrhythmias, long QT syndrome, and the risk of torsades de pointes. The integration of E-4031 into advanced 3D electrophysiological platforms, such as shell MEAs with human cardiac organoids, enables a new era of predictive, high-throughput safety screening. This strategy provides a more physiologically relevant assessment of cardiac repolarization, electro-mechanical coupling, and proarrhythmic substrate formation—surpassing the capabilities of conventional 2D assays.

    Moreover, the ability to observe E-4031-induced changes in activation-recovery intervals, conduction velocity, and action potential propagation in real time—using tools like calcium imaging and multi-site field potential mapping—offers unprecedented insights into arrhythmogenesis and cardiac remodeling. Such data inform not only cardiac safety but also the fundamental mechanisms underlying channelopathies and inherited arrhythmia syndromes.

    Distinguishing Perspectives: Integrating Mechanistic and Translational Approaches

    While articles such as "E-4031: Unlocking 3D Cardiac Electrophysiology with hERG ..." focus on the technical integration of E-4031 in emerging 3D MEA platforms, our discussion synthesizes these technological advances with a mechanistic lens—linking ion channel pharmacology, arrhythmia modeling, and translational research. We emphasize not just the adoption of new tools, but also the interpretive power they unlock when paired with rigorously validated channel blockers like E-4031. This approach facilitates a systems-level understanding of cardiac repolarization, membrane excitability regulation, and the development of next-generation antiarrhythmic therapies.

    Conclusion and Future Outlook

    E-4031, supplied with high purity and validated by APExBIO, remains an indispensable tool in the arsenal of cardiac electrophysiology and ion channel pharmacology. Its selective inhibition of the hERG/IKr potassium channel enables precise modeling of proarrhythmic substrates, QT interval prolongation, and drug-induced arrhythmia. The integration of E-4031 into advanced 3D platforms—such as programmable shell MEAs and human cardiac organoids—ushers in a new era of translational research, bridging the gap between molecular mechanisms and clinical outcomes.

    Looking ahead, continued innovations in 3D bioelectronic interfaces and multi-modal functional analysis promise to further enhance the predictive power of preclinical cardiac safety testing and disease modeling. As the field evolves, the unique mechanistic insights provided by E-4031 will remain central to unraveling the complexities of cardiac ion channel signaling, arrhythmogenesis, and the safe development of novel therapeutics.

    For scientists seeking a reliable, high-purity hERG potassium channel blocker for advanced research applications, E-4031 from APExBIO offers unparalleled performance and versatility. As demonstrated in recent 3D spatiotemporal mapping studies (Choi et al., 2025), the future of cardiac electrophysiology hinges on the synergy between sophisticated pharmacological tools and next-generation bioengineering platforms.